Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(3):173-176
DOI: 10.5428/pcar20180303
Analysis of 1298 cases of adverse drug reactions induced by proton pump inhibitors in military hospitals
1. XIE TingTing(Center of Clinical Pharmacy, General Hospital of PLA,Beijing 100853,China tingting82416@163.com)
2. GUO DaiHong(Center of Clinical Pharmacy, General Hospital of PLA,Beijing 100853,China guodh301@163.com)
3. ZHAO SuYu(Center of Clinical Pharmacy, General Hospital of PLA,Beijing 100853,China )
4. ZHAO Liang(Center of Clinical Pharmacy, General Hospital of PLA,Beijing 100853,China )
5. ZHAO PengZhi(Center of Clinical Pharmacy, General Hospital of PLA,Beijing 100853,China )
ABSTRACT  Objective: To investigate the characteristics and regular patterns of adverse drug reactions (ADRs) induced by proton pump inhibitors(PPIs),and provide references for clinical rational drug use. Methods: Totally, 1298 ADRs induced by PPIs were collected from military ADRs monitoring and management system from January 1,2009 to March 31,2017 by retrospective analysis.The data of gender and age of patients,drug categories,administration routes,dosage forms, systems and organs affected by ADRs and clinical manifestations, relevance evaluation and prognosis were analyzed.Results: In the 1298 ADRs induced by PPIs, there were 84 new and severe cases of ADRs, accounting for 6.47%, with the male to female ratio of 1.29∶1 and age range of (51.58 ± 17.70). Medication routes and dosage forms were mainly intravenous infusion and powder injection. The ADRs were related with 5 kinds of drug categories, with the top 3 drug categories being omeprazole (415 cases, 31.97%), lansoprazole (382 cases, 29.43%) and pantoprazole (297 cases, 22.88%). The ADRs affected multi systems and organs, with a total of 1510 cases-times. The most commonly affected sites were skin and its accessories (400 cases-times, accounting for 26.49%), followed by digestive system damage (248 cases-times, accounting for 16.42%) and systemic damage (244 cases-times, accounting for 16.16%). Conclusion: The risk prevention of PPIs should be strengthed.The use of PPIs should be more rational,and attention should be paid to the ADRs monitoring and drug consultation,so as to reduce or avoid occurrence of ADRs.
Welcome to PCAR! You are the number 70 reader of this article!
Please cite this article as:
XIE TingTing,GUO DaiHong,ZHAO SuYu,ZHAO Liang,ZHAO PengZhi,. Analysis of 1298 cases of adverse drug reactions induced by proton pump inhibitors in military hospitals[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(3): 173-176.
References:
1. LI ChunYan,ZHANG Jie,WANG XiaoHui,et al.Investigation and analysis on the application of proton pump inhibitors in 3005 inpatients[J].Eval Anal Drug-use Hosp China,2017,17(3):406-409. In Chinese with English abstract.
2. State Food and Drug Administration.Management measures for reporting and monitoring of adverse drug reactions(No.81 decree by the Ministry of Health)[EB/OL].(2011-05-24)[2017-08-20].http://www.nhfpc.gov.cn/fzs/s3576/201105/ac4ab24c135a43379f2af1694457f65e.shtml.In Chinese.
3. State Adverse Drug Reaction Monitoring Center.WHO adverse drug reations terminology[M].Beijing:Chinese Medical Science and Technology Press,2003:29-85.In Chinese.
4. State Pharmacopoeia Committee.Pharmacopoeia of the People’s Republic of China.Clinical medication instructions[S].2010 ed.Beijing:Chinese Medical Science and Technology Press,2011:622-852.In Chinese.
5. CHEN XinQian, JIN YouYu, TANG Guang. New materia medica[M].17 ed.Beijing: People’s Medical Publishing House,2011:34-134.In Chinese.
6. XIANG ChunHong.Characteristics and analysis of related factors of adverse drug reactions induced by proton pump inhibitors[J]. Guide China Med,2014,12(24):261-262.In Chinese.
7. WANG DongXiao,ZHU Man,GUO DaiHong,et al.Analysis on 930 cases of ADR/ADE associated with glycopeptides and oxazolidinone antibacterials from military hospitals[J].Chin J Drug Appl Monit,2017,14(1):37-41.In Chinese with English abstract.
8. Thaler H W, Sterke C S, van der Cammen T J. Association of proton pump inhibitor use with recurrent falls and risks of fractures in older women: a study of medication in older fallers[J]. J Nutr Health Aging, 2016, 20(1): 77-81.
9. William J H,Danziger J.Magnesium deficiency and proton-pump inhibitor use:a clinical review[J].J Clin Pharmacol,2016,56(6):660-668.
10. Lee J K,Wu C K,Juang J M,et al.Non-carriers of reduced-function CYP2C19 alleles are most susceptible to impairment of the anti-platelet effect of clopidogrel by proton-pump inhibitors:a pilot study[J].Acta Cardiol Sin,2016,32(2):215-222.
11. WEN XiaoNa,LIU WenSheng,GUO HongYue,et al.Analysis of adverse drug reactions induced by proton pump inhibitors[J].China Pharmacy,2012,23(6):563-565. In Chinese with English abstract.
12. WANG AnQi.Literature analysis of adverse drug reactions induced by proton pump inhibitors[J].Chin J Pharmacovigil,2013,10(11):683-686.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口